Format

Send to

Choose Destination
Oman J Ophthalmol. 2019 May-Aug;12(2):99-103. doi: 10.4103/ojo.OJO_24_2018.

Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration.

Author information

1
Department of Ophthalmology, Tennent Institute of Ophthalmology, Glasgow, Scotland, UK.

Abstract

BACKGROUND:

Aflibercept is widely used as a treatment for neovascular age-related macular degeneration (nAMD). Nevertheless, there is no consensus in the optimal injection frequency in the 2nd year of treatment along with little real-world data on visual outcomes. On that basis, the primary aim of this study was to assess the visual acuity (VA) and the total number of injections needed on average for these patients during the 24-month follow-up.

MATERIALS AND METHODS:

This is a retrospective observational study from an electronic medical record of consecutive patients treated with intravitreal aflibercept (both naïve and nonnaïve eyes) who had completed the 24-month follow-up since the commencement of treatment. Patients followed the VIEW protocol in year 1 whereas in year 2, an as required approach/Pro Re Nata (PRN) was used.

RESULTS:

Eighty-seven eyes of 78 patients were analyzed. 43.7% were nonnaive eyes. Baseline VA for all eyes (logMAR) was 52.6 letters, improving to 56.2 letters at 12 months and 55 at 24 months. Almost 83.9% of the treated eyes (81.3% of the patients) did not experience any significant visual loss receiving on average of 9.9 injections in the 24 months of follow-up and attending the hospital eye service 20.3 times in total.

CONCLUSIONS:

Aflibercept as monotherapy for the treatment of nAMD is associated with good 2 nd year outcomes in a real-world setting using the PRN approach in year 2 and fewer injections comparing to the clinical studies, but a higher proportion of follow-up visits compared to the treat and extend regimen.

KEYWORDS:

Aflibercept; age-related macular degeneration; antivascular endothelial growth factor; real word; visual outcomes

Conflict of interest statement

RP and ME have none. TS has received a travel bursary from Bayer. MG has received travel bursaries and lecture fees from Bayer, Novartis, and Allergan. Bayer was not involved in data collection, analysis, or writing of this paper and has not provided support of any kind.

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center